NASDAQ:APTO
Aptose Biosciences Stock News
$1.23
+0 (+0%)
At Close: Apr 23, 2024
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal
07:45pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
12:44pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
11:30am, Monday, 12'th Sep 2022 GlobeNewswire Inc.
– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure –
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
11:30am, Tuesday, 30'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07:30am, Tuesday, 30'th Aug 2022
SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2022 Results - Earnings Call Transcript
09:00pm, Tuesday, 02'nd Aug 2022
Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
11:30am, Wednesday, 27'th Jul 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
07:30am, Wednesday, 27'th Jul 2022
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
08:01pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase in
Aptose Biosciences Continues To Drift Without Thesis-Changing Data
06:31pm, Tuesday, 19'th Jul 2022
Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pav
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
04:01pm, Tuesday, 19'th Jul 2022
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhi
Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion
03:58pm, Monday, 11'th Jul 2022 Zacks Investment Research
The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
11:30am, Monday, 27'th Jun 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
12:10am, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3
Aptose Presents Highlights from Corporate Update and KOL Event
09:30pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3
